CY1108702T1 - Σκευασματα εμβολιων για τον ιο των ανθρωπινων θηλωματων - Google Patents

Σκευασματα εμβολιων για τον ιο των ανθρωπινων θηλωματων

Info

Publication number
CY1108702T1
CY1108702T1 CY20091100051T CY091100051T CY1108702T1 CY 1108702 T1 CY1108702 T1 CY 1108702T1 CY 20091100051 T CY20091100051 T CY 20091100051T CY 091100051 T CY091100051 T CY 091100051T CY 1108702 T1 CY1108702 T1 CY 1108702T1
Authority
CY
Cyprus
Prior art keywords
human papillomavirus
vaccine formulations
salt
formulations
vlp
Prior art date
Application number
CY20091100051T
Other languages
Greek (el)
English (en)
Inventor
David B Volkin
Li Shi
Henryk Mach
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of CY1108702T1 publication Critical patent/CY1108702T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/108331—Preservative, buffer, anticoagulant or diluent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CY20091100051T 1999-02-05 2009-01-15 Σκευασματα εμβολιων για τον ιο των ανθρωπινων θηλωματων CY1108702T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11872399P 1999-02-05 1999-02-05
EP00905886A EP1150712B1 (en) 1999-02-05 2000-02-01 Human papilloma virus vaccine formulations

Publications (1)

Publication Number Publication Date
CY1108702T1 true CY1108702T1 (el) 2013-09-04

Family

ID=22380362

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100051T CY1108702T1 (el) 1999-02-05 2009-01-15 Σκευασματα εμβολιων για τον ιο των ανθρωπινων θηλωματων

Country Status (15)

Country Link
US (1) US6251678B1 (https=)
EP (1) EP1150712B1 (https=)
JP (2) JP4841726B2 (https=)
KR (1) KR20010093290A (https=)
AR (1) AR022510A1 (https=)
AT (1) ATE413188T1 (https=)
AU (1) AU764138B2 (https=)
CA (1) CA2361837C (https=)
CY (1) CY1108702T1 (https=)
DE (1) DE60040727D1 (https=)
DK (1) DK1150712T3 (https=)
ES (1) ES2313881T3 (https=)
PT (1) PT1150712E (https=)
SI (1) SI1150712T1 (https=)
WO (1) WO2000045841A2 (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA982950B (en) * 1997-04-08 1998-10-19 Merck & Co Inc Stabilized human papillomavirus formulations
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
JP5118798B2 (ja) * 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション アデノウイルス製剤
JP5485489B2 (ja) * 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
CA2327950A1 (en) * 2000-12-08 2002-06-08 Groupe Minutia Inc. Grain refining agent for cast aluminum or magnesium products
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
DE10137102A1 (de) 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
AR038153A1 (es) * 2002-01-18 2004-12-29 Schering Ag Formulaciones estabilizadas de adenovirus
US20040121465A1 (en) * 2002-02-14 2004-06-24 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
PT1572233E (pt) * 2002-12-20 2011-06-07 Glaxosmithkline Biolog Sa Utilização de hpv16 e hpv18 como vacina contra um ou mais de tipos de hpv oncogénicos 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
JP2007001865A (ja) * 2003-09-16 2007-01-11 Ltt Bio-Pharma Co Ltd 脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤
CN1901935A (zh) 2003-12-30 2007-01-24 惠氏公司 具有改进耐受性的免疫原组合物中的疏水性蛋白调配物
US7758866B2 (en) * 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
US7959928B2 (en) * 2004-10-05 2011-06-14 Cytos Biotechnology Ag VLP-antigen conjugates and their uses as vaccines
NZ554388A (en) * 2004-10-05 2010-01-29 Cytos Biotechnology Ag VLP-Antigen conjugates and their uses as vaccines
JP4182074B2 (ja) * 2005-03-03 2008-11-19 ファナック株式会社 ハンド及びハンドリングロボット
CN101171033A (zh) 2005-03-04 2008-04-30 戴纳瓦克斯技术公司 包含具免疫刺激序列iss之寡核苷酸的疫苗：其中iss与抗原缀合并通过缓冲条件和其他赋形剂稳定
EP1877087B1 (en) 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
EP2066354B1 (en) 2006-09-29 2013-04-17 Ligocyte Pharmaceuticals, Inc. Norovirus vaccine formulations
DK2099485T3 (en) * 2006-11-03 2018-05-22 Alphavax Inc Alphavirus and alphavirus replica particle formulations and associated methods
CA2679720A1 (en) * 2007-03-09 2008-09-18 Merck & Co., Inc. Papillomavirus vaccine compositions
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
JP5313231B2 (ja) * 2008-03-31 2013-10-09 森永乳業株式会社 耐熱性を付与する薬剤及び組成物
WO2011079260A2 (en) * 2009-12-23 2011-06-30 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Stabilized virus like particles having enhanced mucosal immunogenicity
CN107913396B (zh) 2010-08-23 2022-03-08 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
WO2012038801A1 (en) 2010-09-21 2012-03-29 National Institute Of Immunology A spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles
RU2610174C2 (ru) * 2011-06-24 2017-02-08 Мерк Шарп И Доум Корп. Вакцинные составы против вируса папилломы человека (hpv), содержащие алюминиевый адъювант, и способы их получения
EP4112074A1 (en) 2011-07-11 2023-01-04 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
TWI570240B (zh) * 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
EP3246400B1 (en) 2012-01-09 2019-10-23 Sanofi Pasteur Biologics, LLC Purification of herpes virus
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP2852662B1 (en) * 2012-05-21 2020-09-16 Sanofi Pasteur Limited Herpesvirus compositions and related methods
EP2865390B1 (en) 2012-06-20 2019-08-21 The University of Tokyo Mucosal immunity-stimulating agent, and oral pharmaceutical composition for treating hpv infection
JOP20130186B1 (ar) * 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
SI3421997T1 (sl) * 2012-12-28 2020-10-30 Cellestis Limited Test celično posredovanega imunskega odziva
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
US9254332B2 (en) * 2013-03-15 2016-02-09 Arecor Limited Stable aqueous formulations of adenovirus vectors
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
US20170212116A1 (en) 2014-01-31 2017-07-27 Ulisse Biomed Srl Biosensors for the detection of infection and associated maladies
CN104479892A (zh) * 2014-11-06 2015-04-01 王越 一种具有植物杀菌功能洗衣液的制备方法
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US12508279B2 (en) 2016-04-01 2025-12-30 Colorado State University Research Foundation Compositions and methods for enhancing innate immunity in a subject for treatment of infections and cancer and other acute and chronic conditions of the eye
EP4483903A3 (en) 2016-04-01 2025-04-02 Colorado State University Research Foundation Compositions and methods for enhanced innate immunity
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
US20210299247A1 (en) * 2017-11-01 2021-09-30 Merck Sharp & Dohme Corp. Stable formulations of cytomegalovirus
CN112439059B (zh) * 2019-09-02 2022-02-08 怡道生物科技(苏州)有限公司 重组人乳头瘤病毒疫苗组合物及其用途
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP2026000483A (ja) * 2022-11-22 2026-01-06 一般財団法人阪大微生物病研究会 安定化されたｖｌｐワクチン
WO2025216920A1 (en) * 2024-04-08 2025-10-16 The Government Of The United States, As Represented By The Secretary Of The Army Freezable aqueous aluminum salt adjuvants

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320782D0 (en) * 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US5569468A (en) * 1994-02-17 1996-10-29 Modi; Pankaj Vaccine delivery system for immunization, using biodegradable polymer microspheres
ATE328068T1 (de) * 1994-05-16 2006-06-15 Merck & Co Inc Papillomavirus vakzine
AUPM566794A0 (en) 1994-05-17 1994-06-09 University Of Queensland, The Process and product
AR004464A1 (es) 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
WO1998013065A1 (en) * 1996-09-26 1998-04-02 Merck & Co., Inc. Rotavirus vaccine formulations
WO1998034594A1 (en) * 1997-02-06 1998-08-13 Merck & Co., Inc. Thimerosal-free preservatives for vaccines
PT973546E (pt) * 1997-04-08 2004-06-30 Merck & Co Inc Formulacoes estabilizadas de virus de papiloma humano

Also Published As

Publication number Publication date
PT1150712E (pt) 2008-12-22
DK1150712T3 (da) 2009-02-02
SI1150712T1 (sl) 2009-02-28
WO2000045841A3 (en) 2000-12-14
WO2000045841A2 (en) 2000-08-10
EP1150712A2 (en) 2001-11-07
AU2749200A (en) 2000-08-25
ES2313881T3 (es) 2009-03-16
JP2002536340A (ja) 2002-10-29
CA2361837C (en) 2011-06-07
JP4841726B2 (ja) 2011-12-21
ATE413188T1 (de) 2008-11-15
DE60040727D1 (de) 2008-12-18
JP2011225578A (ja) 2011-11-10
KR20010093290A (ko) 2001-10-27
AU764138B2 (en) 2003-08-14
AR022510A1 (es) 2002-09-04
US6251678B1 (en) 2001-06-26
EP1150712B1 (en) 2008-11-05
CA2361837A1 (en) 2000-08-10

Similar Documents

Publication Publication Date Title
CY1108702T1 (el) Σκευασματα εμβολιων για τον ιο των ανθρωπινων θηλωματων
UA85536C2 (en) Viral antigens
CY1107457T1 (el) Εμβoλιο κατa του hpv
WO1999033868A3 (en) Human papillomavirus vaccine
BR9812139A (pt) Vacina
DK1450856T3 (da) Pakning af immunstimulatorisk CpG i virus-lignende partilker, fremgangsmåde og anvendelse
DK1113816T3 (da) Influenzavirus-vaccinesammensætning
WO2004042001A3 (en) Virus-like particles, methods of preparation, and immonogenic compositions
ZA200210230B (en) Porcine reproductive and respiratory syndrome virus (PRRSV) recombinant avipoxvirus vaccine.
AU3438900A (en) Use of trehalose for stabilising a liquid vaccine
DK1094837T3 (da) Porcin circovirus og parvovirusvaccine
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
WO2003062407A8 (en) INFECTIOUS cDNA CLONES OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS AND EXPRESSION VECTORS THEREOF
DE60144240D1 (de) Zusammensetzung mit immunogenen mikroteilchen
WO2001068129A3 (de) Adjuvans für vakzinen
AU5137800A (en) Cd4-independent hiv envelope proteins as vaccines and therapeutics
WO2002004007A3 (en) Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof
EP1749885B8 (en) Infectious and attenuated bovine viral diarrhea virus vaccine
AU2001246331A1 (en) Hepatitis b virus (hbv) antigenic polypeptide-heat shock protein complex and use thereof
AU2003294757A1 (en) Formulations useful against hepatitis c virus infections
AR026637A1 (es) Virus atenuados e inocuos de la diarrea virica bovina para uso en vacas gestantes
EP1234023A4 (en) MEMBRANE MUTATION CONCERNING THE VACCINATORY OF A VIRUS AND ITS USE AS A VACCINATE SUBSTRATE
AU2001291050A1 (en) Viral chemokine-tumur antigen fusion proteins
DK1035133T3 (da) Fusionsproteiner, der omfatter bærere, som kan inducere et dobbelt immunrespons
AU2002358235A1 (en) Synchronizing source and destination systems via parallel hash value determinations